Zepp Health

Zepp Health fell sharply during regular trading, closing down 5.3% at $5.15, 91.67% below its 52-week high of $61.85, primarily driven by Q1 earnings which showed revenue up 33.76% YoY to $51.55M but a net loss of $19.64M and EPS loss of $1.2377, extending the loss-making trend. The stock opened at $5.44, briefly hit a session high of $5.59 before sliding to an intraday low of $5.295, dipping below its MA20 of $5.133. Despite a modest post-market bounce to $5.6 on thin volume of 165 shares, the PB stands at just 0.39x and YTD decline is 81.63%. While recent product launches like Amazfit Balance 3 and Helio Strap Pro may support sentiment, Q1 revenue growth slowed from Q4's 43.03% pace.

Zepp Health surged in regular trading today, driven by a 34% YoY revenue increase in Q1 2026 and new product launches, with the stock rebounding from an intraday low of 5.248 to a high of 5.600, closing up 5.9% from the previous close of 5.290. Despite the strong session, the stock remains 80% down YTD and 91% below its 52-week high of 61.85, trading well below both the 20-day MA (5.103) and 60-day MA (8.383), reflecting persistent weakness in the broader trend.

Zepp Health opened lower and continued to decline in regular trading, dropping about 2.96% to $5.24 as of 10:12 ET, mainly due to a brief pre-market spike to $5.40 followed by a rapid pullback, with intraday low hitting $5.062. The Q1 2026 earnings showed revenue up 33.76% YoY to $51.55M, but net loss remained at $19.64M, and EPS of -$1.2377 widened losses by 48% YoY, while the overnight post-market quote held at $5.40, adding downward pressure. The stock is 91.53% below its 52-week high of $61.85 and down 81.31% YTD, though it has reclaimed the MA20 ($5.063), while still trading well below the MA60 ($8.565), indicating short-term support but persistent medium-term weakness.

Zepp Health surged during regular trading after a strong Q1 earnings report, driven by a 33.76% YoY revenue increase to $51.55M, a 50% reduction in net loss, and a 4.81% improvement in operating income. The stock rebounded from a pre-market low of $4.91, rallied to an intraday high of $5.48 by ET 10:55, and closed at $5.48, up 6.61% from the prior close. It broke above the MA20 of $5.046, though year-to-date it remains deeply negative at -80.45%, and sits 91.14% below the 52-week high of $61.85. However, the Non-GAAP EPADS of -$1.13 and a net profit margin of -38.11% continue to weigh on profitability.

Zepp Health dropped 4.9% during regular trading to close at $5.105, driven by persistent Q1 losses and intensifying competition in the wearables market. Although Q1 revenue surged 34% YoY to $51.55M, net loss remained at $19.64M with EPS of -$1.24, worsening from Q4; operating margin widened from -4.5% to -33.9%. The stock slid from $5.37 to an intraday low of $5.06, now 91.75% below its 52-week high of $61.85 but 32.6% above the low of $3.85, while closing above the 5-day moving average. However, new product launches like the Helio Strap Pro and iOS notification support for European smartwatches signal ongoing innovation that could support future revenue.